Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents

Immune targets for therapeutic development in depression: towards precision medicine

(2022) Wayne C. Drevets et al.   NATURE REVIEWS DRUG DISCOVERY

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry

(2022) Hitoshi Sakurai et al.   PHARMACOPSYCHIATRY

PRAX-114 is a Novel Extrasynaptic GABA-A Receptor Preferring Positive Allosteric Modulator With a Wide Separation Between a Translational Biomarker Signature Associated With Antidepressant-Like Activity, and Sedative Effects

(2021) Zoe Hughes et al.   BIOLOGICAL PSYCHIATRY

Trial of Psilocybin versus Escitalopram for Depression

(2021) Robin Carhart-Harris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study

(2021) Adam Savitz et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Effect of Zuranolone vs Placebo in Postpartum Depression

(2021) Kristina M. Deligiannidis et al.   JAMA Psychiatry

Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review

(2021) Amber N. Edinoff et al.   Frontiers in Psychiatry

Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant

(2021) Manish Kumar Jha   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial

(2021) Weifeng Mi et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

(2021) Antony Loebel et al.   JOURNAL OF AFFECTIVE DISORDERS

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms

(2021) Octavian Vasiliu   Frontiers in Psychiatry

Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents

(2020) Molly C. Kalmoe et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Esketamine/ketamine for treatment-resistant depression

(2020) Acioly L.T. Lacerda   REVISTA BRASILEIRA DE PSIQUIATRIA

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study

(2020) George I. Papakostas et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator

(2020) Alison L. Althaus et al.   NEUROPHARMACOLOGY

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making

(2020) Margaret E. Gerbasi et al.   JOURNAL OF WOMENS HEALTH

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

Monoaminergic system and depression

(2019) L. Perez-Caballero et al.   CELL AND TISSUE RESEARCH

Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression

(2019) Roger S. McIntyre et al.   JAMA Psychiatry

SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

(2019) Ethan Hoffmann et al.   CLINICAL PHARMACOKINETICS

Cariprazine for Bipolar Depression: What is the Number Needed to Treat, Number Needed to Harm and Likelihood to be Helped or Harmed?

(2019) Leslie Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

(2019) Michael E. Thase et al.   NEUROPSYCHOPHARMACOLOGY

Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders

(2019) Gayle M. Wittenberg et al.   MOLECULAR PSYCHIATRY

N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects

(2019) Manoela V. Fogaça et al.   NEUROPSYCHOPHARMACOLOGY

Trial of SAGE-217 in Patients with Major Depressive Disorder

(2019) Handan Gunduz-Bruce et al.   NEW ENGLAND JOURNAL OF MEDICINE

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

(2019) Kasper Recourt et al.   Translational Psychiatry

Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression

(2019) Miranda C. Cooper et al.   CNS DRUGS

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders

(2019) Ying Han et al.   Neuroscience Bulletin

Efficacy of adjunctive low-dose cariprazine in major depressive disorder

(2018) Maurizio Fava et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials

(2018) Samantha Meltzer-Brody et al.   LANCET

Structure of a human synaptic GABAA receptor

(2018) Shaotong Zhu et al.   NATURE

Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression

(2018) Clarissa D. Staton et al.   NEUROPHARMACOLOGY

Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression

(2017) Stephen J. Kanes et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor

(2017) Gabriel Martinez Botella et al.   JOURNAL OF MEDICINAL CHEMISTRY

Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial

(2017) Stephen Kanes et al.   LANCET

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

(2017) Christopher E.M. Griffiths et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Sirukumab: A Potential Treatment for Mood Disorders?

(2016) Aileen J. Zhou et al.   ADVANCES IN THERAPY

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

(2016) Susan G. Ball et al.   JOURNAL OF CLINICAL PSYCHIATRY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice

(2016) Ewa Poleszak et al.   METABOLIC BRAIN DISEASE

Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions

(2016) N Kappelmann et al.   MOLECULAR PSYCHIATRY

ACNP 55th Annual Meeting: Poster Session II

(2016)   NEUROPSYCHOPHARMACOLOGY

Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder

(2015) Tina M. Oakes et al.   CURRENT MEDICAL RESEARCH AND OPINION

Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics

(2015) Rafael T. de Sousa et al.   Current Neuropharmacology

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

(2015) Susan G. Ball et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

(2014) Susan Ball et al.   JOURNAL OF AFFECTIVE DISORDERS

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach

(2014) Amir Inamdar et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The role of orexin in motivated behaviours

(2014) Takeshi Sakurai   NATURE REVIEWS NEUROSCIENCE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

The role of allopregnanolone in depression and anxiety

(2013) Cornelius Schüle et al.   PROGRESS IN NEUROBIOLOGY

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study

(2012) Seyed-Hesameddin Abbasi et al.   JOURNAL OF AFFECTIVE DISORDERS

A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression

(2012) Charles L. Raison et al.   JAMA Psychiatry

P.2.c.002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus

(2011) D. Vasile et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

(2011) Beth Pangallo et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

(2008) Edward V. Loftus et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY